CVS Health Agrees to Settle FTC Case Over Insulin Pricing Manipulation

CVS Health has settled a case with the FTC over allegations that its drug benefit manager, Caremark, artificially inflated insulin prices through an illegal rebate system. The deal comes after the FTC claimed that Caremark's actions resulted in higher costs for patients and insurers.